4 Results for "

H1373

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "H1373" in MCE Product Catalog:

Cat. No.: HY-173259
CAS No.: 3071875-24-3
Target:  

PARP

Research Areas:  

Cancer

PARP7-IN-23 (compound 56) is a potent PARP7 inhibitor with an EC50 of 0.915 nM for pSTAT1 in NCI-H1373 cells. PARP7-IN-23 has the potential for cancer research .
loading...
    loading...
Cat. No.: HY-173262
CAS No.: 3072866-54-4
Target:  

PARP

Research Areas:  

Cancer

PARP7-IN-24 (compound 44) is a potent PARP7 inhibitor with an EC50 of 0.375 nM for pSTAT1 in NCI-H1373 cells. PARP7-IN-24 has the potential for cancer research .
loading...
    loading...
Cat. No.: HY-168012
CAS No.: 3054023-07-0
Target:  

Ras Phosphatase

Research Areas:  

Cancer

Pan-RAS-IN-6 (compound 24) is an inhibitor targeting DUSP6, which reduces MAPK activation in the brain of the NCI-H1373-Luc model (DUSP6), at the same time, it shows significant tumor growth inhibition and tumor regression effects in the NSCLC brain metastasis mouse model. Pan-RAS-IN-6 shows high selectivity and strong inhibitory effects, especially in KRAS mutation-related signaling pathways, demonstrating varying inhibitory activity against different KRAS mutants and interacting proteins. The IC50 values for KRAS G12C, G12D, and G12V are 1.3 nM, 4.7 nM, and 0.3 nM, respectively .
loading...
    loading...
Cat. No.: HY-162172
CAS No.: 2819999-00-1
Target:  

PARP

Research Areas:  

Cancer

PARP7-IN-18 is a potent, highly selective, and orally active PARP7 inhibitor with an IC50 of 0.11 nM. PARP7-IN-18 exhibits >1000-fold selectivity over other PARP family members. PARP7-IN-18 inhibits NCI-H1373 lung cancer cell proliferation with an IC50 of 2.5 nM and promotes IFN-β expression. PARP7-IN-18 exhibits favorable pharmacokinetic properties and can be used in research on PARP7-sensitive tumors, such as lung cancer .
loading...
    loading...